Press Releases

Lipidomics Bioinformation Analysis Now Available by Creative Proteomics’s Lipidomics Platform

As a division of Creative Proteomics, Lipidomics is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, biotechnological and pharmaceutical companies. The company has recently announced the launch of fully-developed lipidomics bioinformation analysis service to screen differential lipid molecules and analyze their pathways, revealing the physiological mechanism of their changes.

Creative Proteomics Metabolomics Expands Service Offering with the Launch of Microbial Metabolomics Solutions

Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS based metabolomics services for biomedical research institutions, biotechnology and pharmaceutical companies. With deep industry and business process expertise and a good reputation in providing contract services specialized for metabolomics, Creative Proteomics Metabolomics announced the launch of microbial metabolomics service to promote a comprehensive understanding of microbial physiology.

ERGOMED announces launch of its Rare Disease Innovation Center™

ERGOMED announces launch of its Rare Disease Innovation Center™ Rare Disease Innovation Center to provide strategic guidance and tailored innovative solutions to sponsors focused on rare disease drug development Raleigh, North Carolina, February 28, 2022 – ERGOMED plc (LSE: ERGO) a leading Clinical Research Organization focused on rare disease drug development today announced the establishment of its Rare Disease Innovation Center.

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center

mdgroup to partner with ERGOMED on new Rare Disease Innovation Center Collaboration will provide sponsors with access to industry-leading technology and expertise to optimise rare disease drug development and tackle unmet medical need Bracknell, UK: 28 February 2022 – mdgroup, the leading global provider of personalised clinical study services and technologies, has been selected to provide patient support services to Ergomed’s Rare Disease Innovation Centre.

Rho Awarded NIH-NIAID Contract to Support Clinical Research in Autoimmune Diseases

Research Triangle Park, NC – February 28, 2022 – Rho, a global, full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it has been named the Autoimmune Diseases Statistical and Clinical Coordinating Center (AD-SCCC) for the National Institute of Allergy and Infectious Diseases. As the AD-SCCC, Rho will provide a broad range of services critical for the design, development, execution, and analysis of clinical research in autoimmune diseases. This project has been funded $8.3 million in the first year with Federal funds from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93022C00003. This award has the potential to provide a total of over $49 million to the AD-SCCC over the next five years.

AARDEX Group Joins Innovative IT4Anxiety Project

Innovative medication adherence tools in a real-world hospital setting to reduce anxiety in users of mental health services.

ClinOne Names Clinical Research Technology Leader Andrea Valente Chief Executive Officer

As the newly appointed ClinOne CEO, Andrea Valente brings strategic leadership, industry, product and operational experience needed at a pivotal moment in the company’s exponential growth

Creative Bioarray Develops Cell Immortalization Kits and Immortalized Human Cells to Support Immortalized Cell Research

Qvirus Platform Offers Custom Baculovirus Production to Accelerate High-level Gene Expression

DDA platform Provides In Vitro Skin Absorption Test to Support The Studies in Comestics

Acroscell Releases Voltage-gated Potassium Channels to Accelerate The Development of Drug Development

Creative Biogene Launches A Large Panel of Genome Editing Services to Accelerate Bioprocess of Drug Development

Microbialtec Established A Mature Platform for Escherichia Coli Cultivation to Accelerate Microbial Isolation and Culture

CD Formulation Offers Customized Synthesis to Meet the Demand for Lipid Excipients

As a New York-based CRO company, CD Formulation has keenly observed that the demand for tailored pharmaceutical excipients is on the rise, especially over the past decade, as each formulation project may need unique excipients. In response to such a market trend, the management of CD Formulation earlier this month announces to offer customized synthesis for lipid excipients, which are used in lipid-based dosage forms for the enhancement of drug absorption or delivery.

Nanomaterial News Update: Alfa Chemistry Upgrades Its Nanoprism Product Line

Medix Biochemica announces the launch of its refreshed, and expanding, brand

Medix Biochemica has announced the launch of its refreshed and expanding brand to reflect both the exciting improvements to its offering as a result of recent acquisitions and its ongoing commitment to the in vitro diagnostics (IVD) industry.

World's first Microhub makes spatial context accessible for all

Leica Microsystems has announced a new Mica imaging platform bringing previously inaccessible experiments to all life science researchers.

WuXi STA Passes the First EMA Drug Product Pre-Approval Inspection at its Wuxi City Site

Lonza Leads Market with Large and HLA-Typed CD34+ Cell Lots for Efficient Humanized Mouse Model Development

Lonza has expanded its renowned human stem cell offerings to provide human cord blood CD34+ hematopoietic stem cells (CB-CD34+ HSCs) in large batch sizes, meeting a critical and rapidly expanding market need

UK Regulator Cites CluePoints’ Solutions in Updated Guidance

UK Regulator Cites CluePoints’ Solutions in Updated Guidance MHRA shares CluePoints case study to demonstrate the value of statistical monitoring in clinical trial oversight and monitoring King of Prussia, PA – 7th March 2022: CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Risk-Based Quality Management Software for clinical trials, has been cited in the updated Good Clinical Practice (GCP) guidance from the UK’s MHRA, putting the agency´s considerable weight behind CluePoints’ industry-leading statistical monitoring solutions.